Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoplastic myelodysplastic syndrome.

S Nand1, J E Godwin

  • 1Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois 60153.

Cancer
|September 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway.

Leukemia·2016
Same author

Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.

Leukemia·2012
Same author

Primary talectomy for severe fracture-dislocation of the talus with a 15-year followup: case report.

Foot & ankle international·2007
Same author

Lymphoproliferative disorders in chronic hepatitis C.

Journal of viral hepatitis·2004
Same author

Herpes zoster during treatment with arsenic trioxide.

Annals of hematology·2004
Same author

Superior sagittal sinus thrombosis in a child with Down syndrome.

Journal of paediatrics and child health·2003

Hypoplastic myelodysplastic syndrome (MDS) presents with marrow hypoplasia, distinct from normocellular MDS. This distinct entity shows severe cytopenias, macrocytosis, and a lower risk of leukemia progression, unresponsive to conventional therapies.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
  • MDS is typically characterized by ineffective hematopoiesis and is associated with peripheral cytopenias and a risk of transformation to acute myeloid leukemia.
  • Bone marrow cellularity in MDS can vary, with hypoplastic MDS representing a less common presentation.

Observation:

  • A study compared clinical features, laboratory findings, and outcomes of 11 patients with hypoplastic MDS (marrow cellularity ≤25%) and 53 patients with normo/hypercellular MDS.
  • Patients with hypoplastic MDS presented with lower hemoglobin, more severe leukopenia and thrombocytopenia, and marked macrocytosis (higher MCV).
  • Chromosomal analysis was normal in the hypoplastic MDS group, whereas 23% of the normo/hypercellular group had abnormal karyotypes.

Related Experiment Videos

Findings:

  • Hypoplastic MDS patients exhibited significantly lower leukocyte and platelet counts, and higher mean corpuscular volume (MCV) compared to normo/hypercellular MDS.
  • The incidence of transformation to acute leukemia was lower in the hypoplastic MDS group (11%) versus the normo/hypercellular group (23%).
  • Conventional therapies, including pyridoxine, folic acid, prednisone, anabolic steroids, retinoids, and low-dose cytosine arabinoside, were not beneficial in hypoplastic MDS.

Implications:

  • Hypoplastic MDS appears to be a distinct clinicopathologic entity.
  • The findings suggest that hypoplastic MDS has a unique biological behavior and clinical course.
  • Further research is warranted to understand the pathogenesis and identify effective therapeutic strategies for hypoplastic MDS.